Information Provided By: 
Fly News Breaks for May 17, 2017
XLRN
May 17, 2017 | 05:52 EDT
Goldman analyst Terence Flynn initiated Acceleron with a Sell and a $20 price target saying Luspatercept is the key driver but most opportunities are already reflected in valuation. Flynn said Luspatercept Phase 3 data for two blood disorders isn't expected until mid-2018 and expects shares to be a relative underperformer given the lack of catalysts this year.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
